Veru markets and sells the FC2 Female Condom® (now available by prescription in the US including through the virtual doctor smartphone app “HeyDoctor” at and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation. The company’s division, The Female Health Company, is focused on the global public health sector FC2 business. This division markets the company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.


The FC2 Female Condom® is a thin, soft, loose-fitting sheath made from nitrile (non-latex) which is worn inside the vagina. It has flexible inner and outer rings that hold it in place during sex. It lines the walls of the vagina, allowing the penis to move freely inside the condom during sex, the silicone-based lubricant provides a natural sensation and the non-latex nitrile material heats up to your body temperature.

FC2 Female Condom Internationally

The FC2 international team specializes in FC2 Female Condom programming and training in the U.S. and around the world. They work in partnership with governments, donors and other agencies around the world to build successful reproductive and sexual health programs and policies that integrate FC2 Female Condom.


Premature ejaculation is the most common sexual dysfunction and even more frequent than erectile dysfunction based on epidemiological studies. Premature ejaculation is a self-reported diagnosis. Men with premature ejaculation desire treatment; however, most are reluctant and unlikely to request treatment out of embarrassment. Discrepancies also exist between the man and his partner’s reports of the man’s ejaculatory behavior as women have been found to report premature ejaculation affecting their relationship more often than their male partner.